Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

OBJECTIVE: To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn's disease (CD) naïve to immunosuppressants and biologics using a UK public payer persp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:GUT 2020-04, Vol.69 (4), p.658-664
Hauptverfasser: Panaccione, Remo, Colombel, Jean-Frederic, Travis, Simon P.L, Bossuyt, Peter, Baert, Filip, Vanasek, Tomas, Danalioglu, Ahmet, Novacek, Gottfried, Armuzzi, Alessandro, Reinisch, Walter, Johnson, Scott, Buessing, Marric, Neimark, Ezequiel, Petersson, Joel, Lee, Wan-Ju, D'Haens, Geert R
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:OBJECTIVE: To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn's disease (CD) naïve to immunosuppressants and biologics using a UK public payer perspective. DESIGN: A regression model estimated weekly CD Activity Index (CDAI)-based transition matrices (remission: CDAI
ISSN:0017-5749